regardless of promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial opposition from PBMs. These organizations are frequently building obstacles to reimbursement, such as high expense requirements and approval processes that limit user access. Industry sug